Hence, reinstating SPARC expression in bone DTCs by treatment with either 5-AZA or with COX2 inhibitor NS398 may offer a therapeutic window to treat recurrent prostate cancer disease (Figure 1). This evidence concerns the gene SPARC and prostate cancer.